Darifenacin: first M3 receptor antagonist for overactive bladder

Darifenacin (Emselex) is the first antimuscarinic agent to target the M3 receptor that is associated with detrusor muscle contraction. In our New products review Steve Chaplin presents the clinical data relating to its efficacy and adverse effects, and Professor Christopher Chapple comments on its place in the treatment of overactive bladder. Copyright © 2007 Wiley Interface Ltd